세계 가금류 의약품 시장 규모는 2025년부터 2032년까지 예측 기간 동안 6.17%의 연평균 복합 성장률(CAGR)로 2024년 65억 6,000만 달러에서 2032년에는 105억 9,000만 달러로 성장할 것으로 예측됩니다.
가금류 의약품 시장은 동물의 건강을 뒷받침하는 중요한 분야로 가금류에 대한 의약품, 건강보조제품, 백신 등을 개발 및 공급하는 역할을 담당하고 있습니다. 이 시장은 가금류의 건강을 보호하고 질병을 예방하며 안전한 육류 및 계란 생산을 실현하는 데 중요한 역할을 하고 있습니다. 시장의 대상은 소규모 생산자뿐만 아니라 상업적 양계 사업자에게도 서비스를 제공하고 있으며, 세균성 및 바이러스성 질병, 기생충 질환, 영양 장애 등 다양한 건강 문제에 대응하고 있습니다.
이 시장에서는 항생제, 항바이러스제, 백신, 프로바이오틱스, 면역 및 성장촉진 사료첨가제 등 필수 제품이 제공되고 있습니다. 현재는 항균제 내성에 대한 우려가 높아지면서 식물 유래 식물성 기름래 치료제와 백신, 정밀 건강관리(Precision Health)가 강조되고 있습니다. 또한, 각국의 규제 프레임워크에 따라 제품의 안전성 및 유효성 기준이 설정되어 있으며, 바이오 보안 대책을 통해 질병 발생을 억제하고 있습니다. 가금류 육류와 계란에 대한 수요 증가와 가금류 사육 방법의 개선, 그리고 인수공통전염병에 대한 이해의 진전 등 두 가지 주요 요인이 이 산업의 성장을 뒷받침하고 있습니다. 신흥국에서는 가금류 생산의 확대로 시장이 빠르게 성장하고 있으며, 선진국에서는 첨단 치료 솔루션과 지속 가능한 농업 관행에 초점을 맞춘 성장이 진행되고 있습니다. 향후 생명공학 및 진단 기술의 발전으로 보다 구체적이고 효과적인 치료법이 개발됨에 따라 가금류 의약품 시장은 더욱 발전할 것으로 예측됩니다. 업계는 앞으로도 질병 통제, 생산성 극대화, 윤리적 축산에 중점을 두고 역동적으로 진화해 나갈 것입니다.
세계의 가금류 의약품 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이와 예측, 각종 분류별 상세 분석, 법 및 규제 환경, 임상시험 동향, 사례 분석, 시장 성장에 영향을 미치는 영향요인 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 전해드립니다.
Global poultry pharmaceuticals market is projected to witness a CAGR of 6.17% during the forecast period 2025-2032, growing from USD 6.56 billion in 2024 to USD 10.59 billion in 2032. The poultry pharmaceutical market functions as an essential component of animal health, which creates and distributes medications, together with health products and vaccines for poultry. The market plays a vital role in protecting poultry health while protecting against diseases and producing safe food products. The market serves commercial poultry operations together with smaller producers because it treats various health conditions, which include bacterial and viral diseases, as well as parasitic diseases and nutritional deficiencies.
The market delivers essential products, which include antibiotics together with antivirals and vaccines and probiotics, and feed additives that promote immunity and growth. The industry now focuses on phytogenic solutions together with vaccines and precision health management because of growing antimicrobial resistance concerns. The regulatory frameworks establish product safety standards, and the efficacy standards and biosecurity protocols work to stop disease outbreaks. The industry expands because of two main factors: rising poultry needs and improved farming approaches, and enhanced knowledge of zoonotic diseases. Developing nations experience rapid market expansion because of growing poultry production, while developed nations direct their focus toward advanced therapeutic solutions and sustainable agricultural practices. The future development of poultry pharmaceuticals will follow biotechnology and diagnostic improvements to create specific and effective treatment options. The industry remains dynamic by prioritizing disease control, maximum productivity, and ethical farming practices.
Additionally, to support the market expansion of the poultry pharmaceuticals market, companies are collaborating to enhance production and quality. For instance, in March 2025, RODEC Pharma Ltd signed an exclusive marketing and distribution agreement with UniFAHS to bring next-generation bacteriophage-based solutions to India's poultry, dairy, and pet health sectors. The increasing threat of antimicrobial resistance (AMR) creates a need for bacteriophage solutions because these treatments naturally fight bacterial infections in livestock without harming animals. The product range targets gut health enhancement, together with immunity building and improved animal performance to enable poultry and livestock farmers to minimize antibiotic use while boosting productivity.
Rising Poultry Consumption Drives Global Poultry Pharmaceuticals Market Growth
The global poultry pharmaceutical market experiences quick growth as consumers choose poultry for their protein meal needs. The expanding global population, together with improved economic conditions in developing regions, makes poultry meat and eggs fundamental food sources which result in expanded poultry farming operations. The rising production requirements generated an increased need for vaccines, together with antibiotics and nutritional supplements, which protect poultry health and optimize flock productivity. Poultry health management depends on pharmaceuticals as a key element because they stop food safety problems and shield birds from avian influenza and other disease outbreaks. The private sector, alongside government departments, makes important investments in modern veterinary medicine and vaccination programs, which stimulate market growth. Food safety standards and consumer preference for antibiotic-free poultry products drive the poultry industry toward developing natural healthcare solutions. The poultry industry's rapid growth will drive continuous pharmaceutical industry expansion, which will create sustainable health products for poultry farming.
For instance, in March 2025, Alembic Pharmaceuticals Ltd. entered into a strategic business partnership with Amlan International, which functions as the animal health division of Oil-Dri Corporation of America, to introduce advanced poultry health solutions and this partnership enables broader distribution of sophisticated feed additives, which improve gut health and enhance nutrient uptake and FCR, and deliver enhanced poultry production outcomes to satisfy increasing protein consumption requirements.
Increase in Causes of Poultry Disease Boosts Global Poultry Pharmaceutical Market Demand
The poultry industries face increasing disease outbreaks, which drive higher demand for pharmaceutical products used in their treatment. Farmers implement preventive and therapeutic solutions because disease outbreaks cause major losses through high bird death rates and lowered egg production, and trade limitations. The market for vaccines, together with antibiotics and antiviral drugs, and disinfectants, has increased because these products help protect poultry flocks from infections. The poultry market expansion is supported by government-backed vaccination programs along with biosecurity protocols implemented by poultry producers. Pharmaceutical companies are expanding production capacities and innovating new treatments to meet rising needs. The increasing consumer knowledge about food safety, combined with disease prevention, has resulted in greater use of modern veterinary medical products. The poultry pharmaceutical business will experience major growth because Asia-Pacific and Africa maintain large poultry operations while battling ongoing disease challenges. Pharmaceutical products demonstrate rising demand because these items protect poultry health, which helps maintain worldwide food supply stability.
For instance, in March 2025, Boehringer Ingelheim International GmbH launched its next-generation three-in-one single-dose innovative solution that defends against Bursal, alongside Newcastle and Marek's diseases.
Chicken Animal Type Holds Largest Global Poultry Pharmaceutical Market Share
The poultry pharmaceutical market maintains its biggest segment through chicken products since large-scale farming operations combine with disease prevention needs. Poultry farming operations around the world raise chickens for their meat and eggs, thus exposing them to numerous diseases. The requirement for vaccines, together with antibiotics and health products, emerges from the need to sustain production levels. Large-scale poultry farms require rigorous vaccination and medication protocols to combat avian influenza and Newcastle disease, and coccidiosis, which are common poultry diseases. The pharmaceutical demand rises because broiler chickens grow quickly, while layer chickens need an extended production time. Various countries enforce vaccination rules to protect food safety, which strengthens the market leadership position. The worldwide demand for chicken protein drives ongoing investments in pharmaceutical solutions that boost production efficiency. The pharmaceutical supply chain for chickens is more extensive and standardized than for turkeys and ducks, thus making chickens the main target for veterinary drug manufacturers. The ongoing increase in poultry consumption will sustain this pattern.
For instance, in March 2025, Merck Animal Health, which operates as MSD Animal Health outside of the United States and Canada, announced the approval of NOBILIS MULTRIVA REOm for chicken protection from the European Commission The vaccine functions by actively immunizing chickens so their offspring receive passive immunity which decreases disease symptoms and viraemia caused by avian reovirus (ARV) genotypes 1 and 4. The vaccine also protects against ARV genotypes 2, 3 and 5.
North America Dominates the Global Poultry Pharmaceuticals Market Share
The North America poultry pharmaceutical market shows clear leadership in the global market because of multiple market-driving factors. The region maintains an advanced industrial poultry market through its large-scale commercial operations, which need effective disease prevention and treatment methods. The high per capita poultry meat and egg consumption in North America leads producers to focus on maintaining flock health and productivity, which drives demand for innovative pharmaceutical solutions. The implementation of strict rules combined with active support for animal welfare and food safety stands as a fundamental requirement. Healthcare providers utilize vaccines together with probiotics and nutraceuticals as alternative health solutions because regulatory frameworks promote responsible antibiotic use. The pharmaceutical industry dedicates substantial funds to research and development, while precision farming technologies and advanced diagnostics experience quick adoption to support the ongoing creation of effective poultry health products.
For instance, in August 2024, Elanco Animal Health Incorporated announced a 2500-square-foot expansion of its biological manufacturing facility in Elwood, Kansas and invest USD 130 million, set to be completed by 2026, will support the growth of its monoclonal antibody (mAb) platform, building on the robust expertise already present at this facility.
Impact of U.S. Tariffs on the Global Poultry Pharmaceuticals Market
The implementation of U.S. poultry pharmaceutical tariffs creates a market disturbance that raises production costs for farmers who need imported vaccines, antibiotics, and supplements to protect their flocks. The increased tariffs create supply chain blockages, which raise prices and generate potential shortages that threaten poultry health and lower production output. The poultry business must decide between absorbing price increases into profit margins or charging consumers more, resulting in decreased market sales of poultry products. Producers will pursue cheaper alternatives that could result in inferior products, which threaten both food safety standards and animal welfare conditions. The combined market pressures will lower poultry production volumes, which will decrease meat and egg supply, thus affecting food security. The poultry industry will suffer major damage from these tariffs if effective countermeasures are not implemented.
Key Players Landscape and Outlook
Continuous innovation, together with strategic market adaptation practices, characterizes the landscape of poultry pharmaceuticals. The sector's companies dedicate extensive funds to research and development for creating better poultry health solutions. The development of new vaccines targets both new and recurring diseases while researchers explore probiotic and phytogenic options to reduce antibiotic use due to antimicrobial resistance concerns. These companies choose geographic expansion as their primary strategy to increase their market presence by targeting the rising poultry industries in developing countries. The collaboration between these companies with academic institutions and other biotech firms and local distributors helps them enhance their abilities to develop products while improving their distribution networks. The companies use technological approaches, which include in-ovo vaccination and advanced diagnostics, along with precision farming methods, to create improved disease management tools for worldwide poultry production of healthier and more productive birds.
For instance, in November 2024, Ceva Animal Health (Ceva) launched its innovative Ceva Genesys for automatic and accurate broiler male and female separation at hatch to achieve better flock homogeneity.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.